Skip to main content
OpenTrials

Clinical trial condition

Glomerulosclerosis, Focal Segmental

Explore clinical trials studying Glomerulosclerosis, Focal Segmental. Study availability and eligibility vary by location and protocol.

80 public trials 30 recruiting studies
Refine in advanced search Browse all conditions

Glomerulosclerosis, Focal Segmental trial results

Completed

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

NCT05267262

Conditions
Alport Syndrome, Collagen Diseases, Congenital Abnormalities, +15 more
Locations
  • Investigative Site Los Angeles, California, United States
  • Investigative site Boca Raton, Florida, United States
  • Investigative site Miami, Florida, United States
  • Investigative site Riverview, Florida, United States
View all 22 locations
View Trial Details
Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

NCT04340362

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Glomerulonephritis, +6 more
Locations
  • University of Alabama at Birmingham - The Kirklin Clinic Birmingham, Alabama, United States
  • California Institute of Renal Research San Diego, California, United States
  • The George Washington University Medical Faculty Associates - Kidney Disease & Hypertension Washington D.C., District of Columbia, United States
  • Howard University Hospital Washington D.C., District of Columbia, United States
View all 44 locations
View Trial Details
Completed

PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant

NCT03763643

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • University of Alabama Tuscaloosa, Alabama, United States
  • University of California at Davis Davis, California, United States
  • Lurie Children's Hospital Chicago, Illinois, United States
  • University of Iowa Iowa City, Iowa, United States
View Trial Details
Completed

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX

NCT03366337

Conditions
Abnormalities, Multiple, Autoimmune Diseases, Autosomal Dominant Polycystic Kidney, +21 more
Locations
  • University of Alabama Birmingham Birmingham, Alabama, United States
  • Phoenician Centers for Research & Innovation (PCRI) Phoenix, Arizona, United States
  • University of California Los Angeles Los Angeles, California, United States
  • Denver Nephrology Denver, Colorado, United States
View all 30 locations
View Trial Details
Completed

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

NCT01613118

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +9 more
Locations
  • Balboa Nephrology Medical Group San Diego, California, United States
  • Los Angeles Biomedical Research Institute Torrance, California, United States
  • Colorado Kidney Care Denver, Colorado, United States
  • University of Miami Miller School of Medicine Miami, Florida, United States
View all 33 locations
View Trial Details
Completed

A Study of CCX140-B in Subjects With FSGS

NCT03536754

Conditions
FSGS, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +9 more
Locations
  • AKDHC Phoenix, Arizona, United States
  • Los Angeles Biomedical Research Institute Torrance, California, United States
  • Northwest Louisiana Nephrology Shreveport, Louisiana, United States
  • MGH Boston, Massachusetts, United States
View all 37 locations
View Trial Details
Completed

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

NCT06529796

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis (FSGS), +7 more
Locations
  • Division of Clinical Pharmacology, University of Miami Miami, Florida, United States
  • GCP Research St. Petersburg, Florida, United States
  • Texas Liver Institute San Antonio, Texas, United States
View Trial Details
Completed

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

NCT04009668

Conditions
FSGS, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +14 more
Locations
  • The University of Michigan Ann Arbor, Michigan, United States
  • New York University New York, United States
  • Levine Children's Hospital/Atrium Health Charlotte, North Carolina, United States
  • Cleveland Clinic Foundation Cleveland, Ohio, United States
View Trial Details
Completed

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

NCT05200871

Conditions
Autoimmune Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
Locations
  • Travere Investigational Site San Francisco, California, United States
  • Travere Investigational Site Belmar, New Jersey, United States
  • Travere Investigational Site Chapel Hill, North Carolina, United States
  • Travere Investigational Site King of Prussia, Pennsylvania, United States
View Trial Details
Completed

LDL-Apheresis for FSGS CardioRenal Outcomes

NCT04088799

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Focal Segmental Glomerulosclerosis, +7 more
Locations
  • Cincinnati Children's Hospital Medical Center Cincinnati, Ohio, United States
  • Children's Hospital of Pittsburgh Pittsburgh, Pennsylvania, United States
View Trial Details

Related conditions